Cardinal Health (NYSE: CAH), a leading pharmaceuticals distributor, on Friday reported an increase in adjusted profit for the first quarter of 2025,
Earnings Summary: Everything you need to know about Cardinal Health’s Q1 report
Categories
pharmaceuticals
Infographic: How Merck (MRK) performed in Q3 2024
Merck (NYSE: MRK) reported its third quarter 2024 earnings results today. Sales grew 4% year-over-year to $16.7 billion. Excluding FX, sales growth
Eli Lilly (LLY) Q3 2024 Earnings: Key financials and quarterly highlights
Eli Lilly and Company (NYSE: LLY) reported its third quarter 2024 earnings results today. Worldwide revenue was $11.44 billion, up 20% compared
Key takeaways from Pfizer’s (PFE) Q3 2024 earnings report
Shares of Pfizer Inc. (NYSE: PFE) were down over 1% on Tuesday, despite the company delivering better-than-expected earnings results for the third
PFE Earnings: Key quarterly highlights from Pfizer’s Q3 2024 financial results
Pfizer Inc. (NYSE: PFE) reported its third quarter 2024 earnings results today. Revenues increased 31% year-over-year to $17.7 billion. Revenues increased 32%
Earnings Summary: HCA Healthcare reports Q3 2024 financial results
Hospital operator HCA Healthcare, Inc. (NYSE: HCA) on Friday announced financial and operating results for the third quarter ended September 30, 2024.
Earnings Summary: Everything you need to know about Centene’s Q3 report
Healthcare service provider Centene Corporation (NYSE: CNC) announced third-quarter 2024 results, reporting higher revenue and a decline in adjusted profit. Total revenues
Intuitive Surgical (ISRG) reports double-digit growth in Q3 revenue and earnings
Medical device company Intuitive Surgical, Inc. (NASDAQ: ISRG) has reported a sharp increase in earnings for the third quarter of 2024, reflecting
Johnson & Johnson (JNJ) Q3 2024 Earnings: Key financials and quarterly highlights
Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings results today. Reported sales increased 5.2% year-over-year to $22.5 billion. GAAP earnings
Earnings Preview: Johnson & Johnson bets on innovation to stay in growth mode
Over the years, Johnson & Johnson (NYSE: JNJ) has remained a dominant player in the medical industry, benefitting from its unique business
Walgreens Boots Alliance’s Q4 results likely to reflect market challenges
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) has been struggling to maintain sales momentum and profitability for quite some time due to a
IPO News: Everything you need to know about BioAge Labs’ IPO
BioAge Labs, Inc. is the latest among the healthcare companies pursuing stock-market listing this year. In a registration statement filed with the
Guardian Pharmacy seeks to raise up to $108 mil in US IPO
Joining the wave of healthcare IPOs this year, amid Fed rate cut expectations, Guardian Pharmacy Services, Inc. is preparing to go public.
Everything you need to know about Zenas BioPharma’s IPO
Zenas BioPharma, Inc. is among the latest healthcare companies to jump on the IPO bandwagon, filing its prospectus even as the market
Medtronic bets on innovation and new technology to drive long-term growth
Over the years, Medtronic plc (NYSE: MDT) has constantly strengthened its position in the medical device industry by innovating the product portfolio
Earnings Summary: Highlights of Cardinal Health’s (CAH) Q4 2024 results
Cardinal Health (NYSE: CAH), a leading pharmaceuticals distributor, on Wednesday reported an increase in revenues and adjusted profit for the fourth quarter
Earnings Summary: Gilead Sciences reports higher Q2 revenue and profit
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, has reported an increase in revenues and adjusted earnings for the second
LLY Earnings: Highlights of Eli Lilly’s Q2 2024 financial report
Eli Lilly and Company (NYSE: LLY) on Thursday reported a double-digit increase in revenues and profit for the second quarter of 2024.
Earnings Summary: Moderna reports Q2 2024 financial results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported a sharp decline in revenues for the second quarter of 2024. Second-quarter revenues decreased
Biogen (BIIB) Q2 2024 Earnings: Key financials and quarterly highlights
Biogen Inc. (NASDAQ: BIIB) reported its second quarter 2024 earnings results today. Total revenue of $2.5 billion was flat at actual currency
Merck (MRK) swings to profit in Q2 on higher revenues; earnings beat
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported net profit for the second quarter of 2024, on an adjusted basis, compared